GemPharmatech is proud to announce the launch of NeoMab, our independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation. NeoMab is specifically designed to meet the burgeoning therapeutic antibody development demands of biotechnology companies and pharmaceutical enterprises.
NeoMab™ is developed on the widely recognized BALB/c genetic background, rendering it highly suitable for industry-leading antibody discovery. This model retains the native mouse constant region encoding genes while incorporating human variable gene repertoires into endogenous loci (see Figure 1). This strategy gives rise to a formidable model that synergizes the strengths of the mouse immune system with human-specific variable regions, making it an ideal candidate for propelling antibody discovery and innovative research.
Through extensive in vitro and in vivo experimentation, the NeoMab™ mouse model has exhibited the following exceptional attributes:
- Human-Like Variable Gene Usage Frequency: NeoMab™ mice employ human V(D)J genes to encode antibodies, mirroring gene usage frequency and sequence diversity remarkably similar to those observed in humans.
- Competent Immune System: NeoMab™ mice maintain an intact immune system, with proportions of diverse immune cell subsets akin to those found in BALB/c mice.
- Uninterrupted B-Cell Development: NeoMab™ mice demonstrate unimpeded antibody class switching, somatic hypermutation, and B-cell development. These mice showcase immunoglobulin levels in their serum comparable to those in BALB/c background mice.
- Robust Immune Response: After immunization with antigens, NeoMab™ mice exhibit antigen-specific serum titers similar to BALB/c mice.
Also Read: Veeva R&D and Quality Summit Brings Together Biopharma Leaders to Accelerate Innovation
The antibodies derived from the NeoMab™ mouse model offer the following advantages:
- High Affinity: Antibodies obtained from NeoMab™ mice exhibit an affinity range of approximately 10-10 to 10-8 (as assessed by SPR detection), comparable to or even surpassing that of FDA-approved therapeutic antibody drugs.
- Effective In Vitro and In Vivo Functionality: The in vitro functional activity and in vivo efficacy of NeoMab-derived antibodies closely mirror those observed in FDA-approved therapeutic antibody drugs.
- Reduced Risk of Immunogenicity: These antibodies are less likely to trigger immune responses, due to their higher success rate attributed to the human antibody gene background.
NeoMab, a fully antibody gene humanized model from GemPharmatech, synergizes seamlessly with our advanced technical platform. It not only streamlines preclinical discovery and validation processes for forward-thinking pharmaceutical enterprises but also leverages licensing agreements and high-throughput screening platforms to expedite objectives efficiently and cost-effectively. This approach optimizes capital investment and galvanizes innovative drug development, ultimately paving the way for groundbreaking advancements in the field.
SOURCE: PRNewswire